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To investigate feed as a source for ﬂ  uoroquinolone-
resistant Escherichia coli in broiler chickens, we compared 
antimicrobial drug–resistant E. coli from broiler feed and 
broilers with ciproﬂ  oxacin-resistant human clinical isolates 
by using pulsed-ﬁ  eld gel electrophoresis. Feed was impli-
cated as a source for ciproﬂ  oxacin-resistant broiler-derived 
E. coli and broilers as a source for ciproﬂ  oxacin-resistant 
human-derived E. coli.
I
n a previous study, we found a relatively high prevalence 
of antimicrobial and especially quinolone resistance 
among Escherichia coli isolates from broiler chickens and 
broiler meat (1), despite no known antimicrobial drug se-
lection pressure in chicken farming in Iceland and biosecu-
rity measures to prevent transmission of infectious agents 
into farms. Broiler houses are cleaned and disinfected after 
broiler ﬂ  ocks are transported to slaughter. Therefore, re-
sistant bacteria are unlikely to persist in the broiler houses. 
However, animal feed can be contaminated with antimicro-
bial drug–resistant E. coli (2).
The high prevalence of quinolone-resistant E. coli 
isolates obtained from broilers and broiler meat coincides 
with an increasing prevalence of ﬂ  uoroquinolone resistance 
among human clinical E. coli isolates in Iceland. This in-
crease correlated with increased use of ﬂ  uoroquinolones in 
clinical settings (3).
We examined whether the prevalence of resistant E. 
coli strains in broilers had changed since our previous study 
and whether broiler feed could be a source for the resistant 
strains. Furthermore, we compared the genotypes of cipro-
ﬂ  oxacin-resistant broiler, broiler meat, and broiler feed E. 
coli isolates with ciproﬂ  oxacin-resistant human clinical E. 
coli isolates.
The Study
The sampling period for this study was May through 
November 2008. Pooled cecal samples (20 ceca from each 
ﬂ  ock) were taken from the 30 ﬂ  ocks slaughtered at all 3 
broiler slaughterhouses in Iceland in June 2008. Ceca were 
stomachered in phosphate-buffered saline, spread on Mac-
Conkey agar with and without enroﬂ  oxacin (0.25 mg/L), 
and incubated overnight. Feed was sampled from feed 
stalls at 18 farms (of which 14 had participated in the pre-
vious study) and from 2 feed mills; the feed was suspended 
in buffered peptone water, mixed, incubated overnight, and 
spread on MacConkey agar as described above. One colony 
from each agar plate was selected for susceptibility test-
ing as described in our previous study (1). Because isolates 
were collected from the 18 largest broiler farms (of the 27 
farms operating in Iceland), all the broiler slaughterhouses, 
and the only 2 feed mills operating in Iceland, we believe 
this study provides a representative sample.
We selected all 34 available human E. coli isolates re-
covered from routine clinical specimens (mostly urine and 
blood) at the main clinical microbiology/reference labora-
tory in Iceland (Landspitali University Hospital) during 
2006–2007, which had similar susceptibility patterns to the 
strains previously isolated from broilers (1) (ampicillin-
tetracycline-sulfamethoxazole/trimethoprim-ciproﬂ  oxacin 
or ciproﬂ  oxacin alone). Only 1 isolate was chosen from 
each patient.
We performed susceptibility testing using a microbroth 
dilution method (VetMIC; National Veterinary Institute, 
Uppsala, Sweden). MICs were determined for ampicil-
lin, cefotaxime, ceftiofur, chloramphenicol, ciproﬂ  oxacin, 
ﬂ  orfenicol, gentamicin, nalidixic acid, kanamycin, strepto-
mycin, sulfamethoxazole, tetracycline, and trimethoprim. 
Cutoff values were those used in the monitoring programs 
in Sweden and Norway (4,5). Strains resistant to >3 classes 
of antimicrobial agents were considered multiresistant.
We compared all E. coli broiler ceca and feed iso-
lates resistant to >1 antimicrobial agents and the 34 cip-
roﬂ  oxacin-resistant human E. coli isolates with resistant 
E. coli isolates from the previous study (2005–2007) (1) 
by pulsed-ﬁ  eld gel electrophoresis (PFGE) using a slightly 
modiﬁ  ed method of Ribot et al. (6). Comparison of PFGE 
patterns was made by visual inspection and BioNumerics 
software (Applied Maths, Sint-Martens-Latem, Belgium). 
For cluster analysis, the Dice coefﬁ  cient for band match-
ing (band-position tolerance 1.5%) was used to generate 
an unweighted pair group method with arithmetic averages 
dendrogram. Isolates from the previous and present study 
that did not yield a satisfactory banding pattern by PFGE 
were genotyped by randomly ampliﬁ  ed polymorphic DNA 
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analyzed by electrophoresis on 1.5% agarose gels stained 
with ethidium bromide. Patterns were considered differ-
ent when the proﬁ  les differed by at least 1 band. Similar-
ity among RAPD patterns was compared as described for 
PFGE. Clusters for PFGE and composite RAPD proﬁ  les 
were deﬁ  ned as >2 isolates with >80% similarity. Preva-
lence values were compared by using the Fisher exact test.
Of the 40 broiler isolates, 20 were resistant to >1 of the 
antimicrobial drugs tested (Table); only 1 was multidrug 
resistant (resistant to streptomycin, tetracyclin, sulfame-
thoxazole, and trimethoprim). Ciproﬂ  oxacin and nalidixic 
acid were always cross-resistant. Compared with the previ-
ous sampling, the prevalence of resistance increased signif-
icantly for ciproﬂ  oxacin and nalidixic acid (from 18.2% to 
42.5%; p<0.0001) but decreased signiﬁ  cantly for ampicil-
lin (from 18.2% to 0.0%; p = 0.002) and sulfamethoxazole 
(from 19.1% to 5.0%; p = 0.0398). This ﬁ  nding suggests 
that quinolone resistance was not transferred with resistance 
to the other antimicrobial agents and that it was selected for 
by other factors. Of the 22 E. coli isolates obtained from 
feed, 7 (32%) were resistant to ciproﬂ  oxacin and nalidixic 
acid, and all were susceptible to the other antimicrobial 
agents tested. Although no E. coli were isolated from the 
2 feed mill samples, other Enterobacteriaceae grew on the 
agar plates, which could have overgrown existing E. coli 
strains, if any, demonstrating that the feed was not sterile.
The 27 resistant broiler and feed isolates were com-
pared with 76 resistant isolates analyzed in our previous 
study (1) along with the 34 ciproﬂ  oxacin-resistant human 
E. coli isolates. Of 137 broiler, broiler meat, feed and hu-
man isolates, 110 (80%) yielded interpretable, reproducible 
PFGE patterns. We detected 92 proﬁ  les, of which 81 (88%) 
were represented by a single isolate. Isolates of different 
origin were intermixed forming 26 clusters, of which 12 
were seen in the previous study. Of the 14 new clusters, 
10 contained isolates of different origins (Figure). Human 
isolates clustered with broiler (2005–2006), broiler meat, 
broiler (2008), and feed isolates in 6 clusters (Figure). This 
supports previous ﬁ  ndings of chickens and their products 
as a possible source of antimicrobial drug–resistant E. coli 
in humans (8,9). With the extensive genomic diversity of E. 
coli and the discriminative power of PFGE typing, ﬁ  nding 
indistinguishable isolates of different origin collected over 
several years is unlikely, except from a large collection 
(8,10). Therefore, ﬁ  nding human isolates closely related 
(>80 similarity) to broiler, broiler meat, and feed isolates 
suggests an epidemiologic link between the populations. 
Additionally, we found closely related isolates from feed 
and broiler (samples from 2008 and 2005–2006) from geo-
graphically distant farms, supporting previous ﬁ  ndings that 
antimicrobial drug–resistant E. coli could be introduced 
into the farm environment through broiler feed (2).
The isolates that did not give interpretable PFGE pat-
terns (1 broiler [2005–2006] and 4 broiler meat [2006–
2007] isolates, 11 broiler [2008] and feed [2008] isolates, 
and 11 ciproﬂ  oxacin-resistant human isolates) were sub-
jected to RAPD analysis. All isolates yielded interpretable 
patterns displaying 26 distinct proﬁ  les; all but 1 unique 
proﬁ  le represented a single isolate. At 80% similarity, 1 
cluster was of mixed origin, containing 6 isolates from feed 
and broilers (2008).
Conclusions
Prevalence of ﬂ  uoroquinolone-resistant E. coli remains 
moderately high in broilers, but resistance to other antimi-
crobial drugs is decreasing. Fluoroquinolone-resistant E. 
coli isolated from broiler feed implicates feed as the source 
DISPATCHES
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Table. Antimicrobial drug resistance among Escherichia coli isolates collected from broiler ceca and feed during 2008 compared with 
isolates collected from ceca and meat during 2005–2007 (1), Iceland* 
Resistant strains, no. (%) 
2005–2007  2008 
Antimicrobial drug  Ceca, n = 110  Meat, n = 75  Ceca, n = 40  Feed, n = 22 
Ampicillin  20 (18.2)  12 (16.0)  0  0 
Cefotaxime  0  0  0  0 
Ceftiofur  0  0  0  0 
Chloramphenicol  0  0  0  0 
Ciprofloxacin  20 (18.2)  27 (36.0)  17 (42.5)  7 (31.8) 
Enrofloxacin  16 (14.5)  25 (33.3)  NT
 
NT
 
Florfenicol  1 (0.9)  0  0  0 
Gentamicin  2 (1.8)  1 (1.3)  0  0 
Nalidixic acid  20 (18.2)  27 (36.0)  17 (42.5)  7 (31.8) 
Kanamycin  1 (0.9)  0  0  0 
Streptomycin  9 (8.2)  7 (9.3)  2 (5.0)  0 
Sulfamethoxazole  21 (19.1)  11 (14.7)  2 (5.0)  0 
Tetracycline  15 (13.6)  8 (10.7)  1 (2.5)  0 
Trimethoprim  16 (14.5)  10 (13.3)  1 (2.5)  0 
*NT, not tested. Resistance breakpoints (ȝg/mL): ampicillin, >16; cefotaxime, >0.5; ceftiofur, >2; chloramphenicol, >32; ciprofloxacin, >0.12; enrofloxacin, 
>0.5; florfenicol, >32; gentamicin, >8; nalidixic acid, >32; kanamycin, >16; streptomycin, >64; sulfamethoxazole, >512; tetracycline, >16; trimethoprim, >4. Fluoroquinolone-Resistant Escherichia coli
of resistant strains into farms. Resistant isolates from feed, 
broilers, broiler meat, and humans were closely related, 
demonstrating that poultry and their food products can be a 
source of resistant E. coli in humans.
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Figure. Dendrogram based on unweighted pair group method 
with arithmetic averages cluster analysis of pulsed-ﬁ  eld  gel 
electrophoresis (PFGE) patterns of the 20 broiler (2008), 7 feed 
(2008), and 34 human ciproﬂ  oxacin-resistant  Escherichia coli 
isolates along with 29 of the most closely related broiler (2005–
2006) and broiler meat (2006–2007) isolates from an earlier 
study (1), Iceland. Boxes indicate clusters (isolates with >80% 
similarity by Dice coefﬁ   cient similarity analysis) of isolates of 
different origins not seen in the previous study. Amp, ampicillin; ci, 
ciproﬂ  oxacin; gm, gentamicin; nal, nalidixic acid; sm, streptomycin; 
su, sulfamethoxazole; tc, tetracycline; tm, trimethoprim; tm/su, 
trimethoprim/sulfamethoxazole.